Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05196165 · ClinicalTrials.gov registry record
Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- 14
- Enrollment target
NCT05196165 is a clinical trial that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 14 participants.
The verdict
NCT05196165 was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the incidence of hypoglycemia in adult and pediatric participants with glycogen storage disease type III (GSD III).
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-05-20 |
| Est. Completion | 2023-03-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05196165
The ClinicalTrials.gov registry entry for NCT05196165 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT05196165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05196165 about?
NCT05196165 is a clinical study titled "Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III". The primary objective of this study is to evaluate the incidence of hypoglycemia in adult and pediatric participants with glycogen storage disease type III (GSD III).
What is the current status of trial NCT05196165?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2022-05-20. Estimated completion is 2023-03-02.
What interventions are being tested in trial NCT05196165?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05196165?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.